{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:26:24Z","timestamp":1787214384569,"version":"build-2736575974"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pathological deposition of endogenous material within tissues represents a central, unifying mechanism across a broad spectrum of prevalent human diseases. Atherosclerosis and Alzheimer's disease (AD) exemplify this paradigm: atherosclerosis is driven by subendothelial accumulation of apolipoprotein B\u2013containing lipoproteins, cholesterol crystals, and hydroxyapatite, while AD is characterized by cerebral deposition of misfolded amyloid-\u03b2 (A\u03b2) and\/or hyperphosphorylated tau. Emerging evidence implicates substantial lipid dyshomeostasis in AD pathogenesis, including lipid-droplet-accumulating microglia and widespread lipidomic disruption, blurring the categorical boundary between \"lipid\" and \"protein\" deposition diseases. Apolipoprotein A-I (apoA-I) dysfunction bridges both domains: post-translational modifications and point mutations impair reverse cholesterol transport in atherosclerosis and simultaneously promote apoA-I amyloid fibril formation in systemic amyloidosis. Across atherosclerosis, AD, systemic amyloidoses, immune complex\u2013mediated nephropathies, crystal arthropathies, and lysosomal storage disorders, shared pathophysiologic processes emerge: production\u2013clearance imbalance, conformational transitions favoring aggregation or crystallization, microenvironmental modulation by extracellular matrix components, and chronic sterile inflammatory responses driven by NLRP3 inflammasome activation. In this review, we synthesize deposition biology using atherosclerosis and AD as primary paradigms, integrate mechanistic insights from related disorders, highlight convergent molecular pathways including NLRP3, proteostasis, and glymphatic clearance, and discuss diagnostic and therapeutic strategies. A conceptual framework unifying these conditions as variations on a common deposition theme is proposed to guide broadly applicable precision therapies.<\/jats:p>","DOI":"10.1186\/s43556-026-00552-y","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:18:52Z","timestamp":1787213932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pathological depositions in human disease: converging mechanisms in atherosclerosis, Alzheimer's disease, and related disorders"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8292-5159","authenticated-orcid":false,"given":"Louis","family":"Ragolia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"issue":"2","key":"552_CR1","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2337\/db25-0629","volume":"75","author":"M Uchida","year":"2025","unstructured":"Uchida M, Yamazaki H, Han S, Huang BZ, Ariyoshi S, Hirayama Y, et al. Multiorgan fibrosis and risk of type 2 diabetes: genetic and observational evidence highlighting a causal role of pancreatic fibrosis. Diabetes. 2025;75(2):369\u201378. https:\/\/doi.org\/10.2337\/db25-0629.","journal-title":"Diabetes"},{"issue":"3","key":"552_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3390\/gucdd1030017","volume":"1","author":"T Pascart","year":"2023","unstructured":"Pascart T, Budzik J-F. Does monosodium urate crystal vascular deposition exist? Review of the evidence. Gout Urate Crystal Deposition Dis. 2023;1(3):208\u201316.","journal-title":"Gout Urate Crystal Deposition Dis"},{"issue":"7","key":"552_CR3","doi-asserted-by":"publisher","first-page":"999","DOI":"10.2337\/db22-0962","volume":"72","author":"C-C Hsu","year":"2023","unstructured":"Hsu C-C, Fidler TP, Kanter JE, Kothari V, Kramer F, Tang J, et al. Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis. Diabetes. 2023;72(7):999\u20131011. https:\/\/doi.org\/10.2337\/db22-0962.","journal-title":"Diabetes"},{"issue":"1","key":"552_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s12891-020-03912-z","volume":"22","author":"AE Wininger","year":"2021","unstructured":"Wininger AE, Phelps BM, Le JT, Harris JD, Trachtenberg BH, Liberman SR. Musculoskeletal pathology as an early warning sign of systemic amyloidosis: a systematic review of amyloid deposition and orthopedic surgery. BMC Musculoskelet Disord. 2021;22(1):51. https:\/\/doi.org\/10.1186\/s12891-020-03912-z.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"552_CR5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L, Hansson GK, Deanfield J, Bittencourt MS, et al. Atherosclerosis. Nat Rev Dis Primers. 2019;5(1):56. https:\/\/doi.org\/10.1038\/s41572-019-0106-z.","journal-title":"Nat Rev Dis Primers"},{"issue":"7855","key":"552_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524\u201333. https:\/\/doi.org\/10.1038\/s41586-021-03392-8.","journal-title":"Nature"},{"key":"552_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1146\/annurev-biochem-072611-130030","volume":"82","author":"LM Blancas-Mej\u00eda","year":"2013","unstructured":"Blancas-Mej\u00eda LM, Ramirez-Alvarado M. Systemic amyloidoses. Annu Rev Biochem. 2013;82:745\u201374. https:\/\/doi.org\/10.1146\/annurev-biochem-072611-130030.","journal-title":"Annu Rev Biochem"},{"issue":"3","key":"552_CR8","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/pl00000704","volume":"57","author":"RP Misra","year":"2000","unstructured":"Misra RP. Calcium and disease: molecular determinants of calcium crystal deposition diseases. Cell Mol Life Sci\u202f: CMLS. 2000;57(3):421\u20138. https:\/\/doi.org\/10.1007\/pl00000704.","journal-title":"Cell Mol Life Sci : CMLS"},{"issue":"10","key":"552_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nri3520","volume":"13","author":"KJ Moore","year":"2013","unstructured":"Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709\u201321. https:\/\/doi.org\/10.1038\/nri3520.","journal-title":"Nat Rev Immunol"},{"issue":"10284","key":"552_CR10","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/s0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M, Holstege H, Ch\u00e9telat G, Teunissen CE, et al. Alzheimer\u2019s disease. Lancet. 2021;397(10284):1577\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(20)32205-4.","journal-title":"Lancet"},{"issue":"6","key":"552_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"DJ Selkoe","year":"2016","unstructured":"Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608. https:\/\/doi.org\/10.15252\/emmm.201606210.","journal-title":"EMBO Mol Med"},{"issue":"7293","key":"552_CR12","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357\u201361. https:\/\/doi.org\/10.1038\/nature08938.","journal-title":"Nature"},{"issue":"32","key":"552_CR13","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"7","key":"552_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.amjcard.2008.12.019","volume":"103","author":"GS Abela","year":"2009","unstructured":"Abela GS, Aziz K, Vedre A, Pathak DR, Talbott JD, Dejong J. Effect of cholesterol crystals on plaques and intima in arteries of patients with acute coronary and cerebrovascular syndromes. Am J Cardiol. 2009;103(7):959\u201368. https:\/\/doi.org\/10.1016\/j.amjcard.2008.12.019.","journal-title":"Am J Cardiol"},{"issue":"1","key":"552_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener. 2019;14(1):32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5.","journal-title":"Mol Neurodegener"},{"issue":"9","key":"552_CR16","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698\u2013712. https:\/\/doi.org\/10.1038\/nrd3505.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"552_CR17","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","volume":"101","author":"DM Walsh","year":"2007","unstructured":"Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem. 2007;101(5):1172\u201384. https:\/\/doi.org\/10.1111\/j.1471-4159.2006.04426.x.","journal-title":"J Neurochem"},{"issue":"9","key":"552_CR18","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","volume":"42","author":"PB Gorelick","year":"2011","unstructured":"Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association\/american stroke association. Stroke. 2011;42(9):2672\u2013713. https:\/\/doi.org\/10.1161\/STR.0b013e3182299496.","journal-title":"Stroke"},{"issue":"4","key":"552_CR19","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.neuron.2013.10.008","volume":"80","author":"C Iadecola","year":"2013","unstructured":"Iadecola C. The pathobiology of vascular dementia. Neuron. 2013;80(4):844\u201366. https:\/\/doi.org\/10.1016\/j.neuron.2013.10.008.","journal-title":"Neuron"},{"issue":"10248","key":"552_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/s0140-6736(20)30367-6","volume":"396","author":"G Livingston","year":"2020","unstructured":"Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413\u201346. https:\/\/doi.org\/10.1016\/s0140-6736(20)30367-6.","journal-title":"Lancet"},{"issue":"2","key":"552_CR21","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41591-018-0297-y","volume":"25","author":"DA Nation","year":"2019","unstructured":"Nation DA, Sweeney MD, Montagne A, Sagare AP, D\u2019Orazio LM, Pachicano M, et al. Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction. Nat Med. 2019;25(2):270\u20136. https:\/\/doi.org\/10.1038\/s41591-018-0297-y.","journal-title":"Nat Med"},{"issue":"1","key":"552_CR22","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jalz.2018.07.222","volume":"15","author":"MD Sweeney","year":"2019","unstructured":"Sweeney MD, Montagne A, Sagare AP, Nation DA, Schneider LS, Chui HC, et al. Vascular dysfunction-The disregarded partner of Alzheimer\u2019s disease. Alzheimers Dement. 2019;15(1):158\u201367. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.222.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"552_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1038\/s41392-024-01911-3","volume":"9","author":"J Zhang","year":"2024","unstructured":"Zhang J, Zhang Y, Wang J, Xia Y, Zhang J, Chen L. Recent advances in Alzheimer\u2019s disease: Mechanisms, clinical trials and new drug development strategies. Signal Transduct Target Ther. 2024;9(1):211. https:\/\/doi.org\/10.1038\/s41392-024-01911-3.","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"552_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1038\/nrn3114","volume":"12","author":"BV Zlokovic","year":"2011","unstructured":"Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer\u2019s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723\u201338. https:\/\/doi.org\/10.1038\/nrn3114.","journal-title":"Nat Rev Neurosci"},{"issue":"5","key":"552_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/cjn.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):825\u201335. https:\/\/doi.org\/10.2215\/cjn.05780616.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10055","key":"552_CR26","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1016\/s0140-6736(16)00346-9","volume":"388","author":"N Dalbeth","year":"2016","unstructured":"Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet. 2016;388(10055):2039\u201352. https:\/\/doi.org\/10.1016\/s0140-6736(16)00346-9.","journal-title":"Lancet"},{"issue":"4","key":"552_CR27","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1161\/atvbaha.113.302070","volume":"34","author":"LL Demer","year":"2014","unstructured":"Demer LL, Tintut Y. Inflammatory, metabolic, and genetic mechanisms of vascular calcification. Arterioscler Thromb Vasc Biol. 2014;34(4):715\u201323. https:\/\/doi.org\/10.1161\/atvbaha.113.302070.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"552_CR28","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","volume":"68","author":"RH Falk","year":"2016","unstructured":"Falk RH, Alexander KM, Liao R, Dorbala S. AL (Light-Chain) cardiac amyloidosis: a review of diagnosis and therapy. J Am Coll Cardiol. 2016;68(12):1323\u201341. https:\/\/doi.org\/10.1016\/j.jacc.2016.06.053.","journal-title":"J Am Coll Cardiol"},{"key":"552_CR29","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1750-1172-5-30","volume":"5","author":"DP Germain","year":"2010","unstructured":"Germain DP. Fabry disease. Orphanet J Rare Dis. 2010;5:30. https:\/\/doi.org\/10.1186\/1750-1172-5-30.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"552_CR30","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/nrneph.2013.171","volume":"9","author":"JD Gillmore","year":"2013","unstructured":"Gillmore JD, Hawkins PN. Pathophysiology and treatment of systemic amyloidosis. Nat Rev Nephrol. 2013;9(10):574\u201386. https:\/\/doi.org\/10.1038\/nrneph.2013.171.","journal-title":"Nat Rev Nephrol"},{"key":"552_CR31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1182\/asheducation-2012.1.13","volume":"2012","author":"GA Grabowski","year":"2012","unstructured":"Grabowski GA. Gaucher disease and other storage disorders. Hematology Am Soc Hematol Educ Program. 2012;2012:13\u20138. https:\/\/doi.org\/10.1182\/asheducation-2012.1.13.","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"5","key":"552_CR32","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/mol.0000000000000105","volume":"25","author":"JD Hutcheson","year":"2014","unstructured":"Hutcheson JD, Maldonado N, Aikawa E. Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability. Curr Opin Lipidol. 2014;25(5):327\u201332. https:\/\/doi.org\/10.1097\/mol.0000000000000105.","journal-title":"Curr Opin Lipidol"},{"issue":"1","key":"552_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of vasculitides. Arthritis Rheum. 2013;65(1):1\u201311. https:\/\/doi.org\/10.1002\/art.37715.","journal-title":"Arthritis Rheum"},{"issue":"7081","key":"552_CR34","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, P\u00e9trilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237\u201341. https:\/\/doi.org\/10.1038\/nature04516.","journal-title":"Nature"},{"issue":"11","key":"552_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007\u201316. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","journal-title":"N Engl J Med"},{"issue":"6","key":"552_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583\u201396. https:\/\/doi.org\/10.1056\/NEJMra023144.","journal-title":"N Engl J Med"},{"key":"552_CR37","unstructured":"Neufeld EF MJ. The mucopolysaccharidoses. Valle D ea, editor. New York: McGraw-Hill. 2001."},{"key":"552_CR38","doi-asserted-by":"publisher","first-page":"w13580","DOI":"10.4414\/smw.2012.13580","volume":"142","author":"L Obici","year":"2012","unstructured":"Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med Wkly. 2012;142:w13580. https:\/\/doi.org\/10.4414\/smw.2012.13580.","journal-title":"Swiss Med Wkly"},{"issue":"1","key":"552_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","volume":"4","author":"FM Platt","year":"2018","unstructured":"Platt FM, d\u2019Azzo A, Davidson BL, Neufeld EF, Tifft CJ. Lysosomal storage diseases. Nat Rev Dis Primers. 2018;4(1):27. https:\/\/doi.org\/10.1038\/s41572-018-0025-4.","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"552_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrneph.2012.35","volume":"8","author":"P Ronco","year":"2012","unstructured":"Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol. 2012;8(4):203\u201313. https:\/\/doi.org\/10.1038\/nrneph.2012.35.","journal-title":"Nat Rev Nephrol"},{"issue":"26","key":"552_CR41","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.1056\/NEJMra1511117","volume":"374","author":"AK Rosenthal","year":"2016","unstructured":"Rosenthal AK, Ryan LM. Calcium pyrophosphate deposition disease. N Engl J Med. 2016;374(26):2575\u201384. https:\/\/doi.org\/10.1056\/NEJMra1511117.","journal-title":"N Engl J Med"},{"issue":"2","key":"552_CR42","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/j.1523-1755.2004.00443.x","volume":"65","author":"JJ Weening","year":"2004","unstructured":"Weening JJ, D\u2019Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521\u201330. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00443.x.","journal-title":"Kidney Int"},{"key":"552_CR43","doi-asserted-by":"publisher","unstructured":"Worcester EM, Coe FL. Nephrolithiasis. Prim Care. 2008;35(2):369\u201391, vii. https:\/\/doi.org\/10.1016\/j.pop.2008.01.005.","DOI":"10.1016\/j.pop.2008.01.005"},{"issue":"8","key":"552_CR44","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2337\/dc24-0537","volume":"47","author":"D Qureshi","year":"2024","unstructured":"Qureshi D, Topiwala A, Al Abid SU, Allen NE, Ku\u017ama E, Littlejohns TJ. Association of metabolic syndrome with neuroimaging and cognitive outcomes in the UK Biobank. Diabetes Care. 2024;47(8):1415\u201323. https:\/\/doi.org\/10.2337\/dc24-0537.","journal-title":"Diabetes Care"},{"issue":"10","key":"552_CR45","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.2337\/dc24-0860","volume":"47","author":"A Dove","year":"2024","unstructured":"Dove A, Wang J, Huang H, Dunk MM, Sakakibara S, Guitart-Masip M, et al. Diabetes, prediabetes, and brain aging: the role of healthy lifestyle. Diabetes Care. 2024;47(10):1794\u2013802. https:\/\/doi.org\/10.2337\/dc24-0860.","journal-title":"Diabetes Care"},{"issue":"3","key":"552_CR46","doi-asserted-by":"publisher","first-page":"634","DOI":"10.2337\/dc21-0601","volume":"45","author":"CA Celis-Morales","year":"2022","unstructured":"Celis-Morales CA, Franz\u00e9n S, Eeg-Olofsson K, Naucl\u00e9r E, Svensson A-M, Gudbjornsdottir S, et al. Type 2 diabetes, glycemic control, and their association with dementia and its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022;45(3):634\u201341. https:\/\/doi.org\/10.2337\/dc21-0601.","journal-title":"Diabetes Care"},{"issue":"2","key":"552_CR47","doi-asserted-by":"publisher","first-page":"191","DOI":"10.2174\/156720507780362245","volume":"4","author":"R Deane","year":"2007","unstructured":"Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer\u2019s disease. Curr Alzheimer Res. 2007;4(2):191\u20137. https:\/\/doi.org\/10.2174\/156720507780362245.","journal-title":"Curr Alzheimer Res"},{"issue":"147","key":"552_CR48","doi-asserted-by":"publisher","first-page":"147ra111","DOI":"10.1126\/scitranslmed.3003748","volume":"4","author":"JJ Iliff","year":"2012","unstructured":"Iliff JJ, Wang M, Liao Y, Plogg BA, Peng W, Gundersen GA, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid \u03b2. Sci Transl Med. 2012;4(147):147ra111. https:\/\/doi.org\/10.1126\/scitranslmed.3003748.","journal-title":"Sci Transl Med"},{"issue":"6012","key":"552_CR49","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","volume":"330","author":"KG Mawuenyega","year":"2010","unstructured":"Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, et al. Decreased clearance of CNS beta-amyloid in Alzheimer\u2019s disease. Science. 2010;330(6012):1774. https:\/\/doi.org\/10.1126\/science.1197623.","journal-title":"Science"},{"issue":"3","key":"552_CR50","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/nri2725","volume":"10","author":"J Tschopp","year":"2010","unstructured":"Tschopp J, Schroder K. NLRP3 inflammasome activation: the convergence of multiple signalling pathways on ROS production? Nat Rev Immunol. 2010;10(3):210\u20135. https:\/\/doi.org\/10.1038\/nri2725.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"552_CR51","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/j.1750-3639.2008.00133.x","volume":"18","author":"RO Weller","year":"2008","unstructured":"Weller RO, Subash M, Preston SD, Mazanti I, Carare RO. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer\u2019s disease. Brain Pathol. 2008;18(2):253\u201366. https:\/\/doi.org\/10.1111\/j.1750-3639.2008.00133.x.","journal-title":"Brain Pathol"},{"issue":"2","key":"552_CR52","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1161\/strokeaha.117.016990","volume":"49","author":"SM Greenberg","year":"2018","unstructured":"Greenberg SM, Charidimou A. Diagnosis of cerebral amyloid angiopathy: evolution of the Boston criteria. Stroke. 2018;49(2):491\u20137. https:\/\/doi.org\/10.1161\/strokeaha.117.016990.","journal-title":"Stroke"},{"issue":"3","key":"552_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00535","volume":"22","author":"O Bonnar","year":"2025","unstructured":"Bonnar O, Eyre B, van Veluw SJ. Perivascular brain clearance as a therapeutic target in cerebral amyloid angiopathy and Alzheimer\u2019s disease. Neurotherapeutics. 2025;22(3):e00535. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00535.","journal-title":"Neurotherapeutics"},{"key":"552_CR54","doi-asserted-by":"publisher","unstructured":"Wang L, Han L, Liu S. Dysfunction of the neurovascular unit as a temporal driver in Alzheimer's pathogenesis. Transl Neurodegener. 2026;15(1).\u00a0https:\/\/doi.org\/10.1186\/s40035-026-00548-2.","DOI":"10.1186\/s40035-026-00548-2"},{"issue":"1","key":"552_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01423-w","volume":"16","author":"S Chen","year":"2024","unstructured":"Chen S, Guo D, Zhu Y, Xiao S, Xie J, Zhang Z, et al. Amyloid \u03b2 oligomer induces cerebral vasculopathy via pericyte-mediated endothelial dysfunction. Alzheimers Res Ther. 2024;16(1):56. https:\/\/doi.org\/10.1186\/s13195-024-01423-w.","journal-title":"Alzheimers Res Ther"},{"key":"552_CR56","doi-asserted-by":"publisher","unstructured":"Sharma C, Woo H, Kim SR. Addressing blood-brain barrier impairment in Alzheimer\u2019s disease. Biomedicines. 2022;10(4). https:\/\/doi.org\/10.3390\/biomedicines10040742.","DOI":"10.3390\/biomedicines10040742"},{"key":"552_CR57","doi-asserted-by":"publisher","unstructured":"Cao T, Yang C, Zhang J, Yan Y, Chen Z, Peng X, et al. The underlying role of pericyte-related cerebral lymphatic microcirculation dysfunction in cerebral small vessel disease. Neurobiol Dis. 2025;216:107101. https:\/\/doi.org\/10.1016\/j.nbd.2025.107101.","DOI":"10.1016\/j.nbd.2025.107101"},{"issue":"24","key":"552_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262411843","volume":"26","author":"GK Mansour","year":"2025","unstructured":"Mansour GK, Bolgova O, Hajjar AW, Mavrych V. Neurovascular dysfunction and glymphatic impairment: an unexplored therapeutic frontier in neurodegeneration. Int J Mol Sci. 2025;26(24):11843.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"552_CR59","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106\u201318. https:\/\/doi.org\/10.1038\/nrneurol.2012.263.","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"552_CR60","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1038\/s41467-026-68933-z","volume":"17","author":"AG Contreras","year":"2026","unstructured":"Contreras AG, Walters S, Eissman JM, Archer DB, Regelson AN, Durant A, et al. Genetic modifiers of APOE-\u03b54-associated cognitive decline. Nat Commun. 2026;17(1):2982. https:\/\/doi.org\/10.1038\/s41467-026-68933-z.","journal-title":"Nat Commun"},{"issue":"3","key":"552_CR61","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1097\/01.mol.0000169348.61191.ac","volume":"16","author":"O Gursky","year":"2005","unstructured":"Gursky O. Apolipoprotein structure and dynamics. Curr Opin Lipidol. 2005;16(3):287\u201394. https:\/\/doi.org\/10.1097\/01.mol.0000169348.61191.ac.","journal-title":"Curr Opin Lipidol"},{"issue":"6","key":"552_CR62","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrd4279","volume":"13","author":"BA Kingwell","year":"2014","unstructured":"Kingwell BA, Chapman MJ, Kontush A, Miller NE. HDL-targeted therapies: progress, failures and future. Nat Rev Drug Discov. 2014;13(6):445\u201364. https:\/\/doi.org\/10.1038\/nrd4279.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"552_CR63","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/13506120600960288","volume":"13","author":"L Obici","year":"2006","unstructured":"Obici L, Franceschini G, Calabresi L, Giorgetti S, Stoppini M, Merlini G, et al. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid. 2006;13(4):191\u2013205. https:\/\/doi.org\/10.1080\/13506120600960288.","journal-title":"Amyloid"},{"issue":"9","key":"552_CR64","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.2937","volume":"18","author":"DJ Rader","year":"2012","unstructured":"Rader DJ, Tall AR. The not-so-simple HDL story: Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18(9):1344\u20136. https:\/\/doi.org\/10.1038\/nm.2937.","journal-title":"Nat Med"},{"key":"552_CR65","doi-asserted-by":"publisher","unstructured":"Filtz A, Slipczuk L, Gulati M. Presumed mechanisms underlying Lipoprotein(a)-caused atherosclerosis. Eur Cardiol. 2026;21:e07. https:\/\/doi.org\/10.15420\/ecr.2025.66.","DOI":"10.15420\/ecr.2025.66"},{"key":"552_CR66","doi-asserted-by":"publisher","unstructured":"Cheng CY, Wu YJ, Yeh CF, Huang PH, Hsu CY, Lin TH, et al. 2026 Consensus and review of Lipoprotein(a) from Taiwan Society of Lipid and Atherosclerosis: molecular pathogenesis, epidemiology, clinical implications, and advances in diagnostic strategies. J Formosan Med Assoc. 2026.\u00a0https:\/\/doi.org\/10.1016\/j.jfma.2026.03.073.","DOI":"10.1016\/j.jfma.2026.03.073"},{"issue":"2","key":"552_CR67","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41593-019-0566-1","volume":"23","author":"J Marschallinger","year":"2020","unstructured":"Marschallinger J, Iram T, Zardeneta M, Lee SE, Lehallier B, Haney MS, et al. Lipid-droplet-accumulating microglia represent a dysfunctional and proinflammatory state in the aging brain. Nat Neurosci. 2020;23(2):194\u2013208. https:\/\/doi.org\/10.1038\/s41593-019-0566-1.","journal-title":"Nat Neurosci"},{"key":"552_CR68","doi-asserted-by":"publisher","unstructured":"Sprenger KG, Lietzke EE, Melchior JT, Bruce KD. Lipid and lipoprotein metabolism in microglia: Alzheimer&#x2019;s disease mechanisms and interventions. J Lipid Res. 2025;66(10).https:\/\/doi.org\/10.1016\/j.jlr.2025.100872.","DOI":"10.1016\/j.jlr.2025.100872"},{"key":"552_CR69","doi-asserted-by":"publisher","unstructured":"Sung S, Kim HJ, Cha SJ, Nahm M, Kim SH, Kwon MS. Microglial lipid droplets as therapeutic targets in age-related neurodegenerative diseases. npj Aging. 2025;12(1):2. https:\/\/doi.org\/10.1038\/s41514-025-00295-0.","DOI":"10.1038\/s41514-025-00295-0"},{"issue":"12","key":"552_CR70","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1021\/acschemneuro.6c00284","volume":"17","author":"S Guo","year":"2026","unstructured":"Guo S, Zhang Q, Guo R, Fu L, Zhu H, Zhang Q. Lipid droplet-accumulating microglia as a therapeutic node in neurodegenerative disease. ACS Chem Neurosci. 2026;17(12):2302\u201318. https:\/\/doi.org\/10.1021\/acschemneuro.6c00284.","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"552_CR71","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00803-6","volume":"20","author":"S He","year":"2025","unstructured":"He S, Xu Z, Han X. Lipidome disruption in Alzheimer\u2019s disease brain: detection, pathological mechanisms, and therapeutic implications. Mol Neurodegener. 2025;20(1):11. https:\/\/doi.org\/10.1186\/s13024-025-00803-6.","journal-title":"Mol Neurodegener"},{"key":"552_CR72","doi-asserted-by":"publisher","unstructured":"Fertan E, Meisl G, Klenerman D. Small-diffusible aggregates, plaques, tangles, and dynamic equilibria: Untangling Alzheimer's disease. Alzheimer's Dementia. 2025;21(7):e70462. https:\/\/doi.org\/10.1002\/alz.70462.","DOI":"10.1002\/alz.70462"},{"issue":"1","key":"552_CR73","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-025-08186-8","volume":"17","author":"AA Abdulkhaliq","year":"2026","unstructured":"Abdulkhaliq AA, Kim B, Almoghrabi YM, Khan J, Ajoolabady A, Ren J, et al. Amyloid-\u03b2 and Tau in Alzheimer\u2019s disease: pathogenesis, mechanisms, and interplay. Cell Death Dis. 2026;17(1):21. https:\/\/doi.org\/10.1038\/s41419-025-08186-8.","journal-title":"Cell Death Dis"},{"issue":"1","key":"552_CR74","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1038\/s41467-026-70083-1","volume":"17","author":"X Sun","year":"2026","unstructured":"Sun X, Tang Y, Wang X, Pereira Curia G, Sternke-Hoffmann R, M\u00f6rman C, et al. Alzheimer\u2019s A\u03b2 catalyzes Tau phase separation and aggregation via early nanocluster solubilization. Nat Commun. 2026;17(1):3755. https:\/\/doi.org\/10.1038\/s41467-026-70083-1.","journal-title":"Nat Commun"},{"key":"552_CR75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-biochem-061516-045104","volume":"86","author":"DS Eisenberg","year":"2017","unstructured":"Eisenberg DS, Sawaya MR. Structural studies of amyloid proteins at the molecular level. Annu Rev Biochem. 2017;86:69\u201395. https:\/\/doi.org\/10.1146\/annurev-biochem-061516-045104.","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"552_CR76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0341858","volume":"21","author":"GH Sack Jr","year":"2026","unstructured":"Sack GH Jr, Yun J, Talbot CC Jr, Sethi J. Serum Amyloid A (SAA) induces transcription affecting inflammation. PLoS ONE. 2026;21(2):e0341858. https:\/\/doi.org\/10.1371\/journal.pone.0341858.","journal-title":"PLoS ONE"},{"key":"552_CR77","doi-asserted-by":"publisher","unstructured":"Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC Concise Clinical Guidance. JACC. 2026;87(5):549\u201365. https:\/\/doi.org\/10.1016\/j.jacc.2025.09.004.","DOI":"10.1016\/j.jacc.2025.09.004"},{"issue":"5","key":"552_CR78","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1002\/ajh.70246","volume":"101","author":"MA Gertz","year":"2026","unstructured":"Gertz MA. Immunoglobulin light chain amyloidosis: 2026 update on diagnosis, prognosis, and treatment. Am J Hematol. 2026;101(5):1056\u201369. https:\/\/doi.org\/10.1002\/ajh.70246.","journal-title":"Am J Hematol"},{"issue":"6645","key":"552_CR79","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1038\/42166","volume":"388","author":"MG Spillantini","year":"1997","unstructured":"Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839\u201340. https:\/\/doi.org\/10.1038\/42166.","journal-title":"Nature"},{"issue":"5","key":"552_CR80","doi-asserted-by":"publisher","DOI":"10.1002\/alz.71455","volume":"22","author":"JR Winer","year":"2026","unstructured":"Winer JR, Plastini MJ, Romero A, Vossler H, Sai I, Channappa D, et al. Effects of \u03b1-synuclein pathology on synaptic dysfunction and clinical outcomes in normal aging. Alzheimers Dement. 2026;22(5):e71455. https:\/\/doi.org\/10.1002\/alz.71455.","journal-title":"Alzheimers Dement"},{"issue":"19","key":"552_CR81","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.1021\/acschemneuro.5c00356","volume":"16","author":"A Rana","year":"2025","unstructured":"Rana A, Nikam T, Sreepathi B, Saraf SA, Awasthi S. The aggregation continuum of \u03b1-synuclein and its relevance to brain aging. ACS Chem Neurosci. 2025;16(19):3634\u201352. https:\/\/doi.org\/10.1021\/acschemneuro.5c00356.","journal-title":"ACS Chem Neurosci"},{"key":"552_CR82","doi-asserted-by":"publisher","unstructured":"An Nguyen B, Del Carmen Fernandez-Ramirez M, Bassett P, Singh V, Singh P, P\u0119ka\u0142a M, et al. Structural variability of apolipoprotein A-I amyloid fibrils across organs, mutations, and clinical presentations, revealed by cryo-EM. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.07.08.663734.","DOI":"10.1101\/2025.07.08.663734"},{"issue":"5","key":"552_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167820","volume":"1871","author":"T Prokaeva","year":"2025","unstructured":"Prokaeva T, Jayaraman S, Klimtchuk E, Burke N, Spencer B, Nedelkov D, et al. An unusual phenotype of hereditary AApoAI amyloidosis caused by a novel Asp20Tyr substitution is linked to pH-dependent aggregation of apolipoprotein A-I. Biochimica et Biophysica Acta (BBA). 2025;1871(5):167820. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167820.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"2","key":"552_CR84","doi-asserted-by":"publisher","first-page":"333","DOI":"10.3390\/medsci14020333","volume":"14","author":"A-A Pop","year":"2026","unstructured":"Pop A-A, Bot AL, Botan E, Sparchez M. Renal involvement in pediatric small-vessel vasculitis: a comprehensive review of clinical impact, diagnosis, and management. Med Sci. 2026;14(2):333.","journal-title":"Med Sci"},{"key":"552_CR85","doi-asserted-by":"publisher","unstructured":"Ma S, Chang M, Cui Y, Wang Ha, Liu Y, Zhang S. Molecular immunopharmacology of traditional Chinese medicine\u2013derived compounds in membranous nephropathy: mechanistic insights into immune aging and kidney essence deficiency. Front Immunol. 2026;17:2026.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2026.1770018.","DOI":"10.3389\/fimmu.2026.1770018"},{"key":"552_CR86","doi-asserted-by":"publisher","unstructured":"Guo R, Xue J, Yu R, Xue C, Ma X, Liang J, et al. Autoantibody repertoire in lupus nephritis: from pathogenic mechanisms to clinical integration for precision decision-making. Front Immunol. 2026;17:2026.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2026.1870304.","DOI":"10.3389\/fimmu.2026.1870304"},{"key":"552_CR87","doi-asserted-by":"publisher","unstructured":"Nollet L, Leftheriotis G, Vanakker OMM. Editorial: Cardiovascular calcification: disease mechanisms, clinical phenotypes and therapeutic strategies. Front Cardiovasc Med. 2026;13:2026.\u00a0https:\/\/doi.org\/10.3389\/fcvm.2026.1820272.","DOI":"10.3389\/fcvm.2026.1820272"},{"issue":"10","key":"552_CR88","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/art.43215","volume":"77","author":"R Poulsen","year":"2025","unstructured":"Poulsen R, Dalbeth N. Gout and NLRP3 inflammasome biology. Arthritis Rheumatol. 2025;77(10):1317\u201326. https:\/\/doi.org\/10.1002\/art.43215.","journal-title":"Arthritis Rheumatol"},{"key":"552_CR89","doi-asserted-by":"publisher","unstructured":"Chen Z, Guo Q, Zhang Y, Chen L, Li P, Cheng W, et al. A systems immunology perspective on gout pathogenesis and its precision-targeted treatment strategies. Front Immunol. 2025;16:2025.\u00a0https:\/\/doi.org\/10.3389\/fimmu.2025.1615914.","DOI":"10.3389\/fimmu.2025.1615914"},{"issue":"1","key":"552_CR90","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s00018-026-06086-4","volume":"83","author":"H Adelnia","year":"2026","unstructured":"Adelnia H, Ray S, Ta HT. Decoding vascular calcification: mechanistic insights and translational strategies. Cell Mol Life Sci. 2026;83(1):106. https:\/\/doi.org\/10.1007\/s00018-026-06086-4.","journal-title":"Cell Mol Life Sci"},{"issue":"7","key":"552_CR91","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrm1423","volume":"5","author":"AH Futerman","year":"2004","unstructured":"Futerman AH, van Meer G. The cell biology of lysosomal storage disorders. Nat Rev Mol Cell Biol. 2004;5(7):554\u201365. https:\/\/doi.org\/10.1038\/nrm1423.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"552_CR92","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2337\/dbi22-0040","volume":"72","author":"FM Bowman","year":"2023","unstructured":"Bowman FM, Summers SA, Holland WL. Placing a hex on glucose uptake. Diabetes. 2023;72(6):690\u20132. https:\/\/doi.org\/10.2337\/dbi22-0040.","journal-title":"Diabetes"},{"issue":"5","key":"552_CR93","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00702-025-02925-z","volume":"133","author":"D Erskine","year":"2026","unstructured":"Erskine D, Bronowska AK, Outeiro TF, Attems J. Sphingolipidoses: expanding the spectrum of \u03b1-synucleinopathies. J Neural Transm. 2026;133(5):809\u201321. https:\/\/doi.org\/10.1007\/s00702-025-02925-z.","journal-title":"J Neural Transm"},{"issue":"7","key":"552_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/metabo16070480","volume":"16","author":"G Di Carlo","year":"2026","unstructured":"Di Carlo G, Tommolini ML, Frisco A, Spalluto G, Foley D, Zucchelli M, et al. Metabolomic insights into lysosomal storage diseases: an untargeted view. Metabolites. 2026;16(7):480.","journal-title":"Metabolites"},{"issue":"6","key":"552_CR95","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1042\/bst20240315","volume":"52","author":"H Monkhouse","year":"2024","unstructured":"Monkhouse H, Deane JE. Linking glycosphingolipid metabolism to disease-related changes in the plasma membrane proteome. Biochem Soc Trans. 2024;52(6):2477\u201386. https:\/\/doi.org\/10.1042\/bst20240315.","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"552_CR96","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/a:1021831621210","volume":"4","author":"JI Wolfsdorf","year":"2003","unstructured":"Wolfsdorf JI, Weinstein DA. Glycogen storage diseases. Rev Endocr Metab Disord. 2003;4(1):95\u2013102. https:\/\/doi.org\/10.1023\/a:1021831621210.","journal-title":"Rev Endocr Metab Disord"},{"key":"552_CR97","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101702","author":"V Montalvo-Romeral","year":"2026","unstructured":"Montalvo-Romeral V, Jauze L, Perrot G, Amaouche M, Gardin A, Aguilar Gonz\u00e1lez A, et al. Enhanced lysosomal glycogen breakdown is associated with liver tumorigenesis in glycogen storage disease type III. JHEP Rep. 2026. https:\/\/doi.org\/10.1016\/j.jhepr.2025.101702.","journal-title":"JHEP Rep"},{"issue":"1","key":"552_CR98","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri2675","volume":"10","author":"I Tabas","year":"2010","unstructured":"Tabas I. Macrophage death and defective inflammation resolution in atherosclerosis. Nat Rev Immunol. 2010;10(1):36\u201346. https:\/\/doi.org\/10.1038\/nri2675.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"552_CR99","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"issue":"24","key":"552_CR100","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003.","journal-title":"J Am Coll Cardiol"},{"issue":"7434","key":"552_CR101","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nature11729","volume":"493","author":"MT Heneka","year":"2013","unstructured":"Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, et al. NLRP3 is activated in Alzheimer\u2019s disease and contributes to pathology in APP\/PS1 mice. Nature. 2013;493(7434):674\u20138. https:\/\/doi.org\/10.1038\/nature11729.","journal-title":"Nature"},{"issue":"7784","key":"552_CR102","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"C Ising","year":"2019","unstructured":"Ising C, Venegas C, Zhang S, Scheiblich H, Schmidt SV, Vieira-Saecker A, et al. NLRP3 inflammasome activation drives tau pathology. Nature. 2019;575(7784):669\u201373. https:\/\/doi.org\/10.1038\/s41586-019-1769-z.","journal-title":"Nature"},{"issue":"18","key":"552_CR103","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","volume":"384","author":"MA Mintun","year":"2021","unstructured":"Mintun MA, Lo AC, Duggan Evans C, Wessels AM, Ardayfio PA, Andersen SW, et al. Donanemab in early Alzheimer\u2019s disease. N Engl J Med. 2021;384(18):1691\u2013704. https:\/\/doi.org\/10.1056\/NEJMoa2100708.","journal-title":"N Engl J Med"},{"issue":"1","key":"552_CR104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948.","journal-title":"N Engl J Med"},{"issue":"12","key":"552_CR105","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1182\/blood.2024024719","volume":"146","author":"NA Gort-Freitas","year":"2025","unstructured":"Gort-Freitas NA, Moscvin M, Da Vi\u00e0 MC, Lazzaroni F, Nevone A, Sadigh S, et al. Single-cell and clonal analysis of AL amyloidosis plasma cells and their bone marrow microenvironment. Blood. 2025;146(12):1476\u201392. https:\/\/doi.org\/10.1182\/blood.2024024719.","journal-title":"Blood"},{"issue":"1","key":"552_CR106","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1161\/cir.0000000000000792","volume":"142","author":"MM Kittleson","year":"2020","unstructured":"Kittleson MM, Maurer MS, Ambardekar AV, Bullock-Palmer RP, Chang PP, Eisen HJ, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. Circulation. 2020;142(1):e7\u201322. https:\/\/doi.org\/10.1161\/cir.0000000000000792.","journal-title":"Circulation"},{"issue":"22","key":"552_CR107","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","volume":"73","author":"FL Ruberg","year":"2019","unstructured":"Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872\u201391. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"552_CR108","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/circulationaha.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA Interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431\u201343. https:\/\/doi.org\/10.1161\/circulationaha.118.035831.","journal-title":"Circulation"},{"issue":"32","key":"552_CR109","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000026843","volume":"100","author":"JY Jung","year":"2021","unstructured":"Jung JY, Kim YB, Kim JW, Suh CH, Kim HA. Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: case report and review of literature. Medicine (Baltimore). 2021;100(32):e26843. https:\/\/doi.org\/10.1097\/md.0000000000026843.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"552_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-72150-z","volume":"17","author":"BA Nguyen","year":"2026","unstructured":"Nguyen BA, Fernandez-Ramirez MdC, Bassett P, Singh V, Singh P, P\u0119ka\u0142a M, et al. Cryo-EM reveals structural variability of apolipoprotein A-I amyloid fibrils across organs, mutations, and clinical presentations. Nat Commun. 2026;17(1):5324. https:\/\/doi.org\/10.1038\/s41467-026-72150-z.","journal-title":"Nat Commun"},{"issue":"6","key":"552_CR111","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2009.05.005","volume":"30","author":"SD Brydges","year":"2009","unstructured":"Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, et al. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity. 2009;30(6):875\u201387. https:\/\/doi.org\/10.1016\/j.immuni.2009.05.005.","journal-title":"Immunity"},{"issue":"12","key":"552_CR112","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1681\/asn.2010050472","volume":"21","author":"AS Bomback","year":"2010","unstructured":"Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028\u201335. https:\/\/doi.org\/10.1681\/asn.2010050472.","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"552_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115405","volume":"26","author":"O Arias-Carri\u00f3n","year":"2025","unstructured":"Arias-Carri\u00f3n O, Guerra-Crespo M, Padilla-God\u00ednez FJ, Soto-Rojas LO, Manjarrez E. \u03b1-Synuclein pathology in synucleinopathies: mechanisms, biomarkers, and therapeutic challenges. Int J Mol Sci. 2025;26(11):5405.","journal-title":"Int J Mol Sci"},{"key":"552_CR114","doi-asserted-by":"publisher","first-page":"1103065","DOI":"10.3389\/fmed.2023.1103065","volume":"10","author":"C Sunderk\u00f6tter","year":"2023","unstructured":"Sunderk\u00f6tter C, Golle L, Pillebout E, Michl C. Pathophysiology and clinical manifestations of immune complex vasculitides. Front Med (Lausanne). 2023;10:1103065. https:\/\/doi.org\/10.3389\/fmed.2023.1103065.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"552_CR115","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.neuron.2017.01.018","volume":"93","author":"E Aflaki","year":"2017","unstructured":"Aflaki E, Westbroek W, Sidransky E. The complicated relationship between Gaucher disease and Parkinsonism: insights from a rare disease. Neuron. 2017;93(4):737\u201346. https:\/\/doi.org\/10.1016\/j.neuron.2017.01.018.","journal-title":"Neuron"},{"issue":"45","key":"552_CR116","doi-asserted-by":"publisher","first-page":"19473","DOI":"10.1073\/pnas.1003308107","volume":"107","author":"PK Mistry","year":"2010","unstructured":"Mistry PK, Liu J, Yang M, Nottoli T, McGrath J, Jain D, et al. Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci U S A. 2010;107(45):19473\u20138. https:\/\/doi.org\/10.1073\/pnas.1003308107.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"552_CR117","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ymgme.2012.03.012","volume":"106","author":"MC Patterson","year":"2012","unstructured":"Patterson MC, Hendriksz CJ, Walterfang M, Sedel F, Vanier MT, Wijburg F. Recommendations for the diagnosis and management of Niemann-Pick disease type C: an update. Mol Genet Metab. 2012;106(3):330\u201344. https:\/\/doi.org\/10.1016\/j.ymgme.2012.03.012.","journal-title":"Mol Genet Metab"},{"issue":"6","key":"552_CR118","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1161\/circresaha.110.234914","volume":"109","author":"CM Shanahan","year":"2011","unstructured":"Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res. 2011;109(6):697\u2013711. https:\/\/doi.org\/10.1161\/circresaha.110.234914.","journal-title":"Circ Res"},{"issue":"2","key":"552_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/inm3.70035","volume":"2","author":"W Zhu","year":"2026","unstructured":"Zhu W, Yang S, Chen Z, Yang X, Liang Z, Chen Y. Vascular calcification: mechanisms, models, and therapies. iNew Medicine. 2026;2(2):e70035. https:\/\/doi.org\/10.1002\/inm3.70035.","journal-title":"iNew Medicine"},{"issue":"Pt 11","key":"552_CR120","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1242\/jcs.113.11.1857","volume":"113","author":"B De Strooper","year":"2000","unstructured":"De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci. 2000;113(Pt 11):1857\u201370. https:\/\/doi.org\/10.1242\/jcs.113.11.1857.","journal-title":"J Cell Sci"},{"issue":"5440","key":"552_CR121","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.286.5440.735","volume":"286","author":"R Vassar","year":"1999","unstructured":"Vassar R, Bennett BD, Babu-Khan S, Kahn S, Mendiaz EA, Denis P, et al. Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286(5440):735\u201341. https:\/\/doi.org\/10.1126\/science.286.5440.735.","journal-title":"Science"},{"issue":"6727","key":"552_CR122","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/19077","volume":"398","author":"MS Wolfe","year":"1999","unstructured":"Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity. Nature. 1999;398(6727):513\u20137. https:\/\/doi.org\/10.1038\/19077.","journal-title":"Nature"},{"issue":"2","key":"552_CR123","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","volume":"8","author":"C Haass","year":"2007","unstructured":"Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer\u2019s amyloid beta-peptide. Nat Rev Mol Cell Biol. 2007;8(2):101\u201312. https:\/\/doi.org\/10.1038\/nrm2101.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"552_CR124","doi-asserted-by":"publisher","first-page":"6176","DOI":"10.1038\/ncomms7176","volume":"6","author":"C Condello","year":"2015","unstructured":"Condello C, Yuan P, Schain A, Grutzendler J. Microglia constitute a barrier that prevents neurotoxic protofibrillar A\u03b242 hotspots around plaques. Nat Commun. 2015;6:6176. https:\/\/doi.org\/10.1038\/ncomms7176.","journal-title":"Nat Commun"},{"issue":"2","key":"552_CR125","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa1211851","volume":"368","author":"R Guerreiro","year":"2013","unstructured":"Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E, et al. TREM2 variants in Alzheimer\u2019s disease. N Engl J Med. 2013;368(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1211851.","journal-title":"N Engl J Med"},{"issue":"3","key":"552_CR126","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/ni.3102","volume":"16","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Golenbock DT, Latz E. Innate immunity in Alzheimer\u2019s disease. Nat Immunol. 2015;16(3):229\u201336. https:\/\/doi.org\/10.1038\/ni.3102.","journal-title":"Nat Immunol"},{"issue":"12","key":"552_CR127","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1038\/nn.3554","volume":"16","author":"SE Hickman","year":"2013","unstructured":"Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, et al. The microglial sensome revealed by direct RNA sequencing. Nat Neurosci. 2013;16(12):1896\u2013905. https:\/\/doi.org\/10.1038\/nn.3554.","journal-title":"Nat Neurosci"},{"issue":"7","key":"552_CR128","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland TK, et al. A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell. 2017;169(7):1276-90.e17. https:\/\/doi.org\/10.1016\/j.cell.2017.05.018.","journal-title":"Cell"},{"issue":"6512","key":"552_CR129","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1126\/science.abb8739","volume":"370","author":"M Nedergaard","year":"2020","unstructured":"Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020;370(6512):50\u20136. https:\/\/doi.org\/10.1126\/science.abb8739.","journal-title":"Science"},{"issue":"6156","key":"552_CR130","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1126\/science.1241224","volume":"342","author":"L Xie","year":"2013","unstructured":"Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Thiyagarajan M, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373\u20137. https:\/\/doi.org\/10.1126\/science.1241224.","journal-title":"Science"},{"issue":"5865","key":"552_CR131","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1126\/science.1141448","volume":"319","author":"WE Balch","year":"2008","unstructured":"Balch WE, Morimoto RI, Dillin A, Kelly JW. Adapting proteostasis for disease intervention. Science. 2008;319(5865):916\u20139. https:\/\/doi.org\/10.1126\/science.1141448.","journal-title":"Science"},{"issue":"8","key":"552_CR132","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nrneurol.2017.99","volume":"13","author":"C Hetz","year":"2017","unstructured":"Hetz C, Saxena S. ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol. 2017;13(8):477\u201391. https:\/\/doi.org\/10.1038\/nrneurol.2017.99.","journal-title":"Nat Rev Neurol"},{"issue":"9","key":"552_CR133","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.tcb.2014.05.003","volume":"24","author":"MS Hipp","year":"2014","unstructured":"Hipp MS, Park SH, Hartl FU. Proteostasis impairment in protein-misfolding and -aggregation diseases. Trends Cell Biol. 2014;24(9):506\u201314. https:\/\/doi.org\/10.1016\/j.tcb.2014.05.003.","journal-title":"Trends Cell Biol"},{"issue":"19","key":"552_CR134","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383(19):1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2021372.","journal-title":"N Engl J Med"},{"issue":"27","key":"552_CR135","doi-asserted-by":"publisher","first-page":"20423","DOI":"10.1074\/jbc.R110.134452","volume":"285","author":"EB Vitner","year":"2010","unstructured":"Vitner EB, Platt FM, Futerman AH. Common and uncommon pathogenic cascades in lysosomal storage diseases. J Biol Chem. 2010;285(27):20423\u20137. https:\/\/doi.org\/10.1074\/jbc.R110.134452.","journal-title":"J Biol Chem"},{"key":"552_CR136","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/152786","volume":"2013","author":"A Pirillo","year":"2013","unstructured":"Pirillo A, Norata GD, Catapano AL. LOX-1, OxLDL, and atherosclerosis. Mediators Inflamm. 2013;2013:152786. https:\/\/doi.org\/10.1155\/2013\/152786.","journal-title":"Mediators Inflamm"},{"key":"552_CR137","doi-asserted-by":"publisher","unstructured":"Steinberg D. The LDL modification hypothesis of atherogenesis: an update. J Lipid Res. 2009;50 Suppl(Suppl):S376\u201381. https:\/\/doi.org\/10.1194\/jlr.R800087-JLR200.","DOI":"10.1194\/jlr.R800087-JLR200"},{"key":"552_CR138","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.matbio.2015.02.003","volume":"42","author":"RV Iozzo","year":"2015","unstructured":"Iozzo RV, Schaefer L. Proteoglycan form and function: a comprehensive nomenclature of proteoglycans. Matrix Biol. 2015;42:11\u201355. https:\/\/doi.org\/10.1016\/j.matbio.2015.02.003.","journal-title":"Matrix Biol"},{"issue":"1-2","key":"552_CR139","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s12031-002-0009-3","volume":"19","author":"R Kisilevsky","year":"2002","unstructured":"Kisilevsky R, Szarek WA. Novel glycosaminoglycan precursors as anti-amyloid agents part II. J Mol Neurosci MN. 2002;19(1\u20132):45\u201350. https:\/\/doi.org\/10.1007\/s12031-002-0009-3.","journal-title":"J Mol Neurosci MN"},{"issue":"1","key":"552_CR140","first-page":"120","volume":"56","author":"AD Snow","year":"1987","unstructured":"Snow AD, Willmer J, Kisilevsky R. Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest. 1987;56(1):120\u20133.","journal-title":"Lab Invest"},{"issue":"8","key":"552_CR141","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/s1474-4422(03)00484-8","volume":"2","author":"J van Horssen","year":"2003","unstructured":"van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM. Heparan sulphate proteoglycans in Alzheimer\u2019s disease and amyloid-related disorders. Lancet Neurol. 2003;2(8):482\u201392. https:\/\/doi.org\/10.1016\/s1474-4422(03)00484-8.","journal-title":"Lancet Neurol"},{"issue":"5","key":"552_CR142","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1161\/01.atv.15.5.551","volume":"15","author":"KJ Williams","year":"1995","unstructured":"Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551\u201361. https:\/\/doi.org\/10.1161\/01.atv.15.5.551.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"552_CR143","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1042\/bse0520113","volume":"52","author":"M Yamauchi","year":"2012","unstructured":"Yamauchi M, Sricholpech M. Lysine post-translational modifications of collagen. Essays Biochem. 2012;52:113\u201333. https:\/\/doi.org\/10.1042\/bse0520113.","journal-title":"Essays Biochem"},{"issue":"3","key":"552_CR144","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ni.2001","volume":"12","author":"GK Hansson","year":"2011","unstructured":"Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat Immunol. 2011;12(3):204\u201312. https:\/\/doi.org\/10.1038\/ni.2001.","journal-title":"Nat Immunol"},{"issue":"7","key":"552_CR145","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nri3705","volume":"14","author":"MT Heneka","year":"2014","unstructured":"Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol. 2014;14(7):463\u201377. https:\/\/doi.org\/10.1038\/nri3705.","journal-title":"Nat Rev Immunol"},{"issue":"7685","key":"552_CR146","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature25158","volume":"552","author":"C Venegas","year":"2017","unstructured":"Venegas C, Kumar S, Franklin BS, Dierkes T, Brinkschulte R, Tejera D, et al. Microglia-derived ASC specks cross-seed amyloid-\u03b2 in Alzheimer\u2019s disease. Nature. 2017;552(7685):355\u201361. https:\/\/doi.org\/10.1038\/nature25158.","journal-title":"Nature"},{"issue":"16","key":"552_CR147","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1161\/circulationaha.106.676890","volume":"116","author":"I Tabas","year":"2007","unstructured":"Tabas I, Williams KJ, Bor\u00e9n J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116(16):1832\u201344. https:\/\/doi.org\/10.1161\/circulationaha.106.676890.","journal-title":"Circulation"},{"issue":"11","key":"552_CR148","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1038\/nm.2538","volume":"17","author":"C Weber","year":"2011","unstructured":"Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic options. Nat Med. 2011;17(11):1410\u201322. https:\/\/doi.org\/10.1038\/nm.2538.","journal-title":"Nat Med"},{"issue":"5","key":"552_CR149","doi-asserted-by":"publisher","DOI":"10.1002\/clc.70305","volume":"49","author":"A Habib","year":"2026","unstructured":"Habib A, Khan MSM, Aneeq A, Tahir HMT, Mehmoodi A, Malik J, et al. Apolipoprotein A-I (CSL112) and cardiovascular outcomes in atherosclerotic cardiovascular disease: a scoping review. Clin Cardiol. 2026;49(5):e70305. https:\/\/doi.org\/10.1002\/clc.70305.","journal-title":"Clin Cardiol"},{"issue":"2","key":"552_CR150","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","volume":"15","author":"AR Tall","year":"2015","unstructured":"Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104\u201316. https:\/\/doi.org\/10.1038\/nri3793.","journal-title":"Nat Rev Immunol"},{"issue":"4","key":"552_CR151","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/circresaha.115.306246","volume":"118","author":"MG Sorci-Thomas","year":"2016","unstructured":"Sorci-Thomas MG, Thomas MJ. Microdomains, inflammation, and atherosclerosis. Circ Res. 2016;118(4):679\u201391. https:\/\/doi.org\/10.1161\/circresaha.115.306246.","journal-title":"Circ Res"},{"issue":"4","key":"552_CR152","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1172\/jci21109","volume":"114","author":"L Zheng","year":"2004","unstructured":"Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, et al. Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J Clin Invest. 2004;114(4):529\u201341. https:\/\/doi.org\/10.1172\/jci21109.","journal-title":"J Clin Invest"},{"issue":"6","key":"552_CR153","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1021\/bi011716p","volume":"41","author":"JK Bielicki","year":"2002","unstructured":"Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry. 2002;41(6):2089\u201396. https:\/\/doi.org\/10.1021\/bi011716p.","journal-title":"Biochemistry"},{"issue":"5","key":"552_CR154","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2025.167820","volume":"1871","author":"T Prokaeva","year":"2025","unstructured":"Prokaeva T, Jayaraman S, Klimtchuk E, Burke N, Spencer B, Nedelkov D, et al. An unusual phenotype of hereditary AApoAI amyloidosis caused by a novel Asp20Tyr substitution is linked to pH-dependent aggregation of apolipoprotein A-I. Biochim Biophys Acta (BBA) - Mol Basis Dis. 2025;1871(5): 167820. https:\/\/doi.org\/10.1016\/j.bbadis.2025.167820.","journal-title":"Biochim Biophys Acta (BBA) - Mol Basis Dis"},{"issue":"9","key":"552_CR155","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.2337\/db23-0167","volume":"73","author":"AW Khan","year":"2024","unstructured":"Khan AW, Aziz M, Sourris KC, Lee MKS, Dai A, Watson AMD, et al. The role of activator protein-1 complex in diabetes-associated atherosclerosis: insights from single-cell RNA sequencing. Diabetes. 2024;73(9):1495\u2013512. https:\/\/doi.org\/10.2337\/db23-0167.","journal-title":"Diabetes"},{"issue":"7","key":"552_CR156","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s11883-022-01025-7","volume":"24","author":"A Kalayci","year":"2022","unstructured":"Kalayci A, Gibson CM, Ridker PM, Wright SD, Kingwell BA, Korjian S, et al. ApoA-I infusion therapies following acute coronary syndrome: past, present, and future. Curr Atheroscler Rep. 2022;24(7):585\u201397. https:\/\/doi.org\/10.1007\/s11883-022-01025-7.","journal-title":"Curr Atheroscler Rep"},{"issue":"22","key":"552_CR157","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.jacc.2024.03.396","volume":"83","author":"TJ Povsic","year":"2024","unstructured":"Povsic TJ, Korjian S, Bahit MC, Chi G, Duffy D, Alexander JH, et al. Effect of reconstituted human apolipoprotein A-I on recurrent ischemic events in survivors of acute MI. J Am Coll Cardiol. 2024;83(22):2163\u201374.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"552_CR158","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5551\/jat.65669","volume":"33","author":"H Qi","year":"2026","unstructured":"Qi H, Ogura M, Matsuda K, Miida T. Enhancement of ABCA1 and ABCG1 expression and cholesterol efflux by a metabolite of tipelukast: a potential therapeutic strategy for atherosclerosis. J Atheroscler Thromb. 2026;33(1):55\u201377. https:\/\/doi.org\/10.5551\/jat.65669.","journal-title":"J Atheroscler Thromb"},{"key":"552_CR159","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26167908","author":"HE Rajha","year":"2025","unstructured":"Rajha HE, Hassanein A, Mesilhy R, Nurulhaque Z, Elghoul N, Burgon PG, et al. Apolipoprotein A (ApoA) in neurological disorders: connections and insights. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26167908.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"552_CR160","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1002\/eji.201141719","volume":"41","author":"E Thorp","year":"2011","unstructured":"Thorp E, Subramanian M, Tabas I. The role of macrophages and dendritic cells in the clearance of apoptotic cells in advanced atherosclerosis. Eur J Immunol. 2011;41(9):2515\u20138. https:\/\/doi.org\/10.1002\/eji.201141719.","journal-title":"Eur J Immunol"},{"issue":"26","key":"552_CR161","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381(26):2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"},{"issue":"10","key":"552_CR162","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/eurheartj\/ehs411","volume":"34","author":"E Falk","year":"2013","unstructured":"Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists\u2019 view. Eur Heart J. 2013;34(10):719\u201328. https:\/\/doi.org\/10.1093\/eurheartj\/ehs411.","journal-title":"Eur Heart J"},{"issue":"8 Suppl","key":"552_CR163","doi-asserted-by":"publisher","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","volume":"47","author":"R Virmani","year":"2006","unstructured":"Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. J Am Coll Cardiol. 2006;47(8 Suppl):C13\u20138. https:\/\/doi.org\/10.1016\/j.jacc.2005.10.065.","journal-title":"J Am Coll Cardiol"},{"issue":"10105","key":"552_CR164","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1016\/s0140-6736(17)32247-x","volume":"390","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ. Effect of interleukin-1\u03b2 inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10105):1833\u201342. https:\/\/doi.org\/10.1016\/s0140-6736(17)32247-x.","journal-title":"Lancet"},{"issue":"8","key":"552_CR165","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, et al. Amyloid-beta protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat Med. 2008;14(8):837\u201342. https:\/\/doi.org\/10.1038\/nm1782.","journal-title":"Nat Med"},{"key":"552_CR166","doi-asserted-by":"publisher","first-page":"262","DOI":"10.3389\/fnagi.2016.00262","volume":"8","author":"J Avila","year":"2016","unstructured":"Avila J, Jim\u00e9nez JS, Sayas CL, Bol\u00f3s M, Zabala JC, Rivas G, et al. Tau structures. Front Aging Neurosci. 2016;8:262. https:\/\/doi.org\/10.3389\/fnagi.2016.00262.","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"552_CR167","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/bf00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82(4):239\u201359. https:\/\/doi.org\/10.1007\/bf00308809.","journal-title":"Acta Neuropathol"},{"issue":"7","key":"552_CR168","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/ncb1901","volume":"11","author":"F Clavaguera","year":"2009","unstructured":"Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank S, Probst A, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol. 2009;11(7):909\u201313. https:\/\/doi.org\/10.1038\/ncb1901.","journal-title":"Nat Cell Biol"},{"issue":"19","key":"552_CR169","doi-asserted-by":"publisher","first-page":"12845","DOI":"10.1074\/jbc.M808759200","volume":"284","author":"B Frost","year":"2009","unstructured":"Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem. 2009;284(19):12845\u201352. https:\/\/doi.org\/10.1074\/jbc.M808759200.","journal-title":"J Biol Chem"},{"issue":"10","key":"552_CR170","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","volume":"23","author":"MA Busche","year":"2020","unstructured":"Busche MA, Hyman BT. Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease. Nat Neurosci. 2020;23(10):1183\u201393. https:\/\/doi.org\/10.1038\/s41593-020-0687-6.","journal-title":"Nat Neurosci"},{"issue":"6","key":"552_CR171","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","volume":"46","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957\u201367. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.006.","journal-title":"Immunity"},{"issue":"5","key":"552_CR172","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.neuron.2019.12.007","volume":"105","author":"AA Nugent","year":"2020","unstructured":"Nugent AA, Lin K, van Lengerich B, Lianoglou S, Przybyla L, Davis SS, et al. TREM2 regulates microglial cholesterol metabolism upon chronic phagocytic challenge. Neuron. 2020;105(5):837-54.e9. https:\/\/doi.org\/10.1016\/j.neuron.2019.12.007.","journal-title":"Neuron"},{"issue":"5","key":"552_CR173","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/ng.803","volume":"43","author":"P Hollingworth","year":"2011","unstructured":"Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A\/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer\u2019s disease. Nat Genet. 2011;43(5):429\u201335. https:\/\/doi.org\/10.1038\/ng.803.","journal-title":"Nat Genet"},{"issue":"12","key":"552_CR174","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1038\/ng.2802","volume":"45","author":"JC Lambert","year":"2013","unstructured":"Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer\u2019s disease. Nat Genet. 2013;45(12):1452\u20138. https:\/\/doi.org\/10.1038\/ng.2802.","journal-title":"Nat Genet"},{"key":"552_CR175","doi-asserted-by":"publisher","unstructured":"Stancu IC, Lodder C, Botella Lucena P, Vanherle S, Guti\u00e9rrez de Rav\u00e9 M, Terwel D, et al. The NLRP3 inflammasome modulates tau pathology and neurodegeneration in a tauopathy model. Glia. 2022;70(6):1117\u201332. https:\/\/doi.org\/10.1002\/glia.24160.","DOI":"10.1002\/glia.24160"},{"issue":"1","key":"552_CR176","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/circresaha.115.306656","volume":"118","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection. Circ Res. 2016;118(1):145\u201356. https:\/\/doi.org\/10.1161\/circresaha.115.306656.","journal-title":"Circ Res"},{"issue":"5","key":"552_CR177","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrn3012","volume":"12","author":"G Di Paolo","year":"2011","unstructured":"Di Paolo G, Kim TW. Linking lipids to Alzheimer\u2019s disease: cholesterol and beyond. Nat Rev Neurosci. 2011;12(5):284\u201396. https:\/\/doi.org\/10.1038\/nrn3012.","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"552_CR178","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1161\/01.str.18.2.311","volume":"18","author":"HV Vinters","year":"1987","unstructured":"Vinters HV. Cerebral amyloid angiopathy. A critical review. Stroke. 1987;18(2):311\u201324. https:\/\/doi.org\/10.1161\/01.str.18.2.311.","journal-title":"Stroke"},{"issue":"4","key":"552_CR179","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrneph.2015.206","volume":"12","author":"HJ Anders","year":"2016","unstructured":"Anders HJ, Jayne DR, Rovin BH. Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat Rev Nephrol. 2016;12(4):205\u201316. https:\/\/doi.org\/10.1038\/nrneph.2015.206.","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"552_CR180","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.2353\/ajpath.2009.080814","volume":"174","author":"JJ Hoozemans","year":"2009","unstructured":"Hoozemans JJ, van Haastert ES, Nijholt DA, Rozemuller AJ, Eikelenboom P, Scheper W. The unfolded protein response is activated in pretangle neurons in Alzheimer\u2019s disease hippocampus. Am J Pathol. 2009;174(4):1241\u201351. https:\/\/doi.org\/10.2353\/ajpath.2009.080814.","journal-title":"Am J Pathol"},{"issue":"8","key":"552_CR181","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1158\/2159-8290.Cd-24-0002","volume":"14","author":"J Prakash","year":"2024","unstructured":"Prakash J, Shaked Y. The interplay between extracellular matrix remodeling and cancer therapeutics. Cancer Discov. 2024;14(8):1375\u201388. https:\/\/doi.org\/10.1158\/2159-8290.Cd-24-0002.","journal-title":"Cancer Discov"},{"issue":"1","key":"552_CR182","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2008.03.036","volume":"52","author":"HF Langer","year":"2008","unstructured":"Langer HF, Haubner R, Pichler BJ, Gawaz M. Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol. 2008;52(1):1\u201312. https:\/\/doi.org\/10.1016\/j.jacc.2008.03.036.","journal-title":"J Am Coll Cardiol"},{"issue":"10c","key":"552_CR183","doi-asserted-by":"publisher","first-page":"18l","DOI":"10.1016\/s0002-9149(02)02957-0","volume":"90","author":"DH O'Leary","year":"2002","unstructured":"O\u2019Leary DH, Polak JF. Intima-media thickness: a tool for atherosclerosis imaging and event prediction. Am J Cardiol. 2002;90(10c):18l\u201321l. https:\/\/doi.org\/10.1016\/s0002-9149(02)02957-0.","journal-title":"Am J Cardiol"},{"issue":"25","key":"552_CR184","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1093\/eurheartj\/ehy217","volume":"39","author":"MJ Budoff","year":"2018","unstructured":"Budoff MJ, Young R, Burke G, Jeffrey Carr J, Detrano RC, Folsom AR, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. 2018;39(25):2401\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehy217.","journal-title":"Eur Heart J"},{"issue":"8","key":"552_CR185","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/nrcardio.2014.80","volume":"11","author":"JM Tarkin","year":"2014","unstructured":"Tarkin JM, Joshi FR, Rudd JH. PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 2014;11(8):443\u201357. https:\/\/doi.org\/10.1038\/nrcardio.2014.80.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"552_CR186","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"WE Klunk","year":"2004","unstructured":"Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol. 2004;55(3):306\u201319. https:\/\/doi.org\/10.1002\/ana.20009.","journal-title":"Ann Neurol"},{"issue":"2","key":"552_CR187","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/ana.24321","volume":"77","author":"R Ossenkoppele","year":"2015","unstructured":"Ossenkoppele R, Schonhaut DR, Baker SL, O\u2019Neil JP, Janabi M, Ghosh PM, et al. Tau, amyloid, and hypometabolism in a patient with posterior cortical atrophy. Ann Neurol. 2015;77(2):338\u201342. https:\/\/doi.org\/10.1002\/ana.24321.","journal-title":"Ann Neurol"},{"issue":"4","key":"552_CR188","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018.","journal-title":"Alzheimers Dement"},{"issue":"24","key":"552_CR189","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1161\/circulationaha.116.021612","volume":"133","author":"JD Gillmore","year":"2016","unstructured":"Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404\u201312. https:\/\/doi.org\/10.1161\/circulationaha.116.021612.","journal-title":"Circulation"},{"issue":"6","key":"552_CR190","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","volume":"69","author":"S Tsimikas","year":"2017","unstructured":"Tsimikas S. A Test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol. 2017;69(6):692\u2013711. https:\/\/doi.org\/10.1016\/j.jacc.2016.11.042.","journal-title":"J Am Coll Cardiol"},{"issue":"9533","key":"552_CR191","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/s0140-6736(06)69113-7","volume":"368","author":"K Blennow","year":"2006","unstructured":"Blennow K, de Leon MJ, Zetterberg H. Alzheimer\u2019s disease. Lancet. 2006;368(9533):387\u2013403. https:\/\/doi.org\/10.1016\/s0140-6736(06)69113-7.","journal-title":"Lancet"},{"issue":"5","key":"552_CR192","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/s1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2020;19(5):422\u201333. https:\/\/doi.org\/10.1016\/s1474-4422(20)30071-5.","journal-title":"Lancet Neurol"},{"issue":"5","key":"552_CR193","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol. 2021;141(5):709\u201324. https:\/\/doi.org\/10.1007\/s00401-021-02275-6.","journal-title":"Acta Neuropathol"},{"issue":"5","key":"552_CR194","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","volume":"3","author":"O Hansson","year":"2023","unstructured":"Hansson O, Blennow K, Zetterberg H, Dage J. Blood biomarkers for Alzheimer\u2019s disease in clinical practice and trials. Nat Aging. 2023;3(5):506\u201319. https:\/\/doi.org\/10.1038\/s43587-023-00403-3.","journal-title":"Nat Aging"},{"issue":"22","key":"552_CR195","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA. 2016;316(22):2373\u201384. https:\/\/doi.org\/10.1001\/jama.2016.16951.","journal-title":"JAMA"},{"issue":"13","key":"552_CR196","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","volume":"295","author":"SE Nissen","year":"2006","unstructured":"Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556\u201365. https:\/\/doi.org\/10.1001\/jama.295.13.jpc60002.","journal-title":"JAMA"},{"issue":"18","key":"552_CR197","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1615664.","journal-title":"N Engl J Med"},{"issue":"16","key":"552_CR198","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray KK, Wright RS, Kallend D, Koenig W, Leiter LA, Raal FJ, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1912387.","journal-title":"N Engl J Med"},{"issue":"14","key":"552_CR199","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1080\/14656566.2024.2409324","volume":"25","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Tan S, Butters J, Nelson AJ. Evaluating obicetrapib as an emerging treatment for patients with dyslipidemia: a game changer? Expert Opin Pharmacother. 2024;25(14):1879\u201385. https:\/\/doi.org\/10.1080\/14656566.2024.2409324.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"552_CR200","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"1","key":"552_CR201","doi-asserted-by":"publisher","DOI":"10.1186\/alzrt233","volume":"6","author":"TE Golde","year":"2014","unstructured":"Golde TE. Open questions for Alzheimer\u2019s disease immunotherapy. Alzheimers Res Ther. 2014;6(1):3. https:\/\/doi.org\/10.1186\/alzrt233.","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"552_CR202","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1080\/13543784.2019.1683160","volume":"28","author":"BP Imbimbo","year":"2019","unstructured":"Imbimbo BP, Watling M. Investigational BACE inhibitors for the treatment of Alzheimer\u2019s disease. Expert Opin Investig Drugs. 2019;28(11):967\u201375. https:\/\/doi.org\/10.1080\/13543784.2019.1683160.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"552_CR203","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/alz.12213","volume":"17","author":"DS Knopman","year":"2021","unstructured":"Knopman DS, Jones DT, Greicius MD. Failure to demonstrate efficacy of aducanumab: an analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019. Alzheimers Dement. 2021;17(4):696\u2013701. https:\/\/doi.org\/10.1002\/alz.12213.","journal-title":"Alzheimers Dement"},{"key":"552_CR204","doi-asserted-by":"publisher","unstructured":"Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. [Not Available]. Alzheimers Dement (N Y). 2024;10(2):e12465. https:\/\/doi.org\/10.1002\/trc2.12465.","DOI":"10.1002\/trc2.12465"},{"key":"552_CR205","doi-asserted-by":"publisher","unstructured":"Cox TM. Substrate reduction therapy for lysosomal storage diseases. Acta Paediatr Suppl. 2005;94(447):69\u201375; discussion 57. https:\/\/doi.org\/10.1111\/j.1651-2227.2005.tb02116.x.","DOI":"10.1111\/j.1651-2227.2005.tb02116.x"},{"issue":"1","key":"552_CR206","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","volume":"29","author":"T Coelho","year":"2013","unstructured":"Coelho T, Maurer MS, Suhr OB. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin. 2013;29(1):63\u201376. https:\/\/doi.org\/10.1185\/03007995.2012.754348.","journal-title":"Curr Med Res Opin"},{"issue":"12","key":"552_CR207","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1056\/NEJMra1300575","volume":"372","author":"DC Rockey","year":"2015","unstructured":"Rockey DC, Bell PD, Hill JA. Fibrosis--a common pathway to organ injury and failure. N Engl J Med. 2015;372(12):1138\u201349. https:\/\/doi.org\/10.1056\/NEJMra1300575.","journal-title":"N Engl J Med"},{"issue":"1","key":"552_CR208","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.cell.2019.02.024","volume":"177","author":"I Barroso","year":"2019","unstructured":"Barroso I, McCarthy MI. The genetic basis of metabolic disease. Cell. 2019;177(1):146\u201361. https:\/\/doi.org\/10.1016\/j.cell.2019.02.024.","journal-title":"Cell"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00552-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00552-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T08:18:58Z","timestamp":1787213938000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00552-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":208,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["552"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00552-y","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"assertion":[{"value":"15 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N\/A.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N\/A.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"145"}}